Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05548426 · ClinicalTrials.gov registry record · Phase 2

Linezolid for Syphilis Pilot Study

A Phase 2 study of Syphilis, sponsored by University of Southern California.

Active
Registry status
Phase 2
Development phase
24
Enrollment target
5
Study locations

NCT05548426 is a Phase 2 study of Syphilis that is active but no longer recruiting, run by University of Southern California. The registered enrollment target is 24 participants, below the 270-participant average among 6 other Syphilis trials with a reported enrollment target (91% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05548426, a Phase 2 study of Syphilis, is active but no longer recruiting, sponsored by University of Southern California.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
24 participants
Enrollment target
5
Study locations

Study Summary

The study aims to evaluate the efficacy of linezolid for the treatment of syphilis.

Conditions Studied

Interventions

  • DRUG Group B, Linezolid 10d
  • DRUG Group A, Penicillin

Study Locations (5)

Mississippi

  • Open Arms HealthCare Center - Jackson
  • University of Mississippi Medical Center - Jackson

Illinois

  • Howard Brown Health - Chicago

North Carolina

  • Wake Forest Baptist Health - Greensboro

Rhode Island

  • Open Door Health - Providence

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2023-09-28
Est. Completion 2026-08
Phase Phase 2

Sponsor

University of Southern California

617 total trials

What the Registry Record Tells You About NCT05548426

The ClinicalTrials.gov registry entry for NCT05548426 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 270-participant average among 6 other Syphilis trials with a reported enrollment target (91% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Syphilis appearing as the primary indexed condition, and to 2 interventions - of which Group B, Linezolid 10d is the first listed.

NCT05548426 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Mississippi, Illinois, North Carolina.

Frequently Asked Questions

What is clinical trial NCT05548426 about?

NCT05548426 is a clinical study titled "Linezolid for Syphilis Pilot Study". The study aims to evaluate the efficacy of linezolid for the treatment of syphilis.

What is the current status of trial NCT05548426?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2023-09-28. Estimated completion is 2026-08.

What conditions does trial NCT05548426 study?

This clinical trial studies the following conditions: Syphilis.

What interventions are being tested in trial NCT05548426?

The interventions under investigation include: Group B, Linezolid 10d (DRUG), Group A, Penicillin (DRUG).

Who is sponsoring clinical trial NCT05548426?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05548426 being conducted?

This trial has 5 study locations across Illinois, Mississippi, North Carolina, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Syphilis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.